Centessa Pharmaceuticals’ (CNTA) Buy Rating Reiterated at Guggenheim

Guggenheim reaffirmed their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research report report published on Wednesday morning,Benzinga reports. The firm currently has a $28.00 price objective on the stock.

Several other brokerages have also recently issued reports on CNTA. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Stock Up 0.6 %

NASDAQ:CNTA opened at $14.59 on Wednesday. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a 50-day moving average of $16.48 and a 200 day moving average of $16.41. The firm has a market cap of $1.92 billion, a PE ratio of -9.54 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. As a group, research analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the transaction, the chief executive officer now owns 429,398 shares in the company, valued at approximately $6,771,606.46. This represents a 11.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the sale, the general counsel now owns 118,265 shares of the company’s stock, valued at $1,808,271.85. The trade was a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 260,168 shares of company stock worth $4,309,568 in the last ninety days. 11.59% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at about $31,000. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after buying an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Centessa Pharmaceuticals during the 4th quarter worth approximately $171,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.